c(RGDfK) polypeptide binds to αvβ3 receptor and can inhibit cell activities related to this receptor, such as tumor cell adhesion and migration. c(RGDfK) peptide is an RGD tumor-targeting peptide and a highly efficient and selective inhibitor of αvβ3 integrin receptor. It binds to αvβ3 receptors, interferes with or blocks the interaction between αvβ3 receptors and ligand molecules, thereby inhibiting the adhesion and migration of tumor cells, thereby achieving anti-tumor effects.
The αvβ3 receptor is a cell surface receptor that participates in the interaction between cells and the extracellular matrix and plays an important role in biological processes such as cell adhesion, migration, and proliferation. The αvβ3 receptor plays a key role in tumor angiogenesis, metastasis and invasion, and is therefore considered a potential target for anti-cancer therapy. c(RGDfK) polypeptide inhibits the adhesion and migration of tumor cells by binding to αvβ3 receptors, thereby inhibiting tumor proliferation and metastasis. In addition, it can induce apoptosis and differentiation of tumor cells, thereby achieving anti-tumor therapeutic effects.
In short, the combination of c(RGDfK) peptide and αvβ3 receptor can inhibit the adhesion and migration of tumor cells, thereby achieving anti-tumor effects. This interaction is useful in tumor targeted therapy, antithrombotic therapy, diagnostic imaging, and immune regulation. It has broad application prospects. Therefore, c(RGDfK) peptide is a bioactive peptide with broad application prospects.
English
